Scholarlink

<p>The purpose of this study is to explore the role in MCTP2 glioblastoma (GBM) relapse and associated therapy target, especially its function on immune suppression together with drug-resistance. We performed transcriptional analysis of primary and recurrent GBM samples from the TCGA and CGGA databases to identify a key regulatory gene in relation to synaptic-related pathways using MCTP2. We used single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics analysis of expression in GBM samples to explore the population landscapes as well as tumor region-specific features at the molecular level. Functional studies via Western blotting, colony-formation assays and patient-derived organoid (PDO) models were used to assess the effect of MCTP2-depletion with/without SB52334 treatment in GBM. MCTP2 is significantly up-regulated in recurrent GBM and it correlates with poor survival. In addition, the increased expression of immune checkpoint markers PD-L1 (CD274) and CTLA-4 were significantly associated with high MCTP2 levels, indicating that MCTP2 could affect GBM patients' responses to anti-PD-1/PD-L1 or/and anti-CTLAs therapies. Overexpression of MCTP2 was also related to the increase in drug-resistance, specifically against SB52334. Combining MCTP2 KD with SB52334 significantly decreased primary cell clonogenic potential and organoid viability, suggesting a synergistic effect. MCTP2 plays a distinct role in GBM, acting as a novel facilitator of immune evasion and drug resistance with potential therapeutic implications. Our findings suggest that combining MCTP2 knockdown with SB52334 treatment could enhance the therapeutic efficacy against GBM.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Investigating the impact of MCTP2 on immune suppression and drug resistance in glioblastoma

  • 期刊论文

  • 发表日期：

    2025年11月26日

查看全文
  • Yiguang Chen,
  • Xiaorong Yan,
  • Qin Huang,
  • Huishen Pang,
  • Chengyu Li,
  • Xin Su,
  • Yongyi Ye,
  • Ziyu Wang,
  • Yongjian Chen,
  • Yiqiang Zhou

摘要

The purpose of this study is to explore the role in MCTP2 glioblastoma (GBM) relapse and associated therapy target, especially its function on immune suppression together with drug-resistance. We performed transcriptional analysis of primary and recurrent GBM samples from the TCGA and CGGA databases to identify a key regulatory gene in relation to synaptic-related pathways using MCTP2. We used single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics analysis of expression in GBM samples to explore the population landscapes as well as tumor region-specific features at the molecular level. Functional studies via Western blotting, colony-formation assays and patient-derived organoid (PDO) models were used to assess the effect of MCTP2-depletion with/without SB52334 treatment in GBM. MCTP2 is significantly up-regulated in recurrent GBM and it correlates with poor survival. In addition, the increased expression of immune checkpoint markers PD-L1 (CD274) and CTLA-4 were significantly associated with high MCTP2 levels, indicating that MCTP2 could affect GBM patients' responses to anti-PD-1/PD-L1 or/and anti-CTLAs therapies. Overexpression of MCTP2 was also related to the increase in drug-resistance, specifically against SB52334. Combining MCTP2 KD with SB52334 significantly decreased primary cell clonogenic potential and organoid viability, suggesting a synergistic effect. MCTP2 plays a distinct role in GBM, acting as a novel facilitator of immune evasion and drug resistance with potential therapeutic implications. Our findings suggest that combining MCTP2 knockdown with SB52334 treatment could enhance the therapeutic efficacy against GBM.